vs
科睿唯安（CLVT）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是Pediatrix Medical Group, Inc.的1.2倍（$585.5M vs $493.8M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs -6.9%，领先13.7%），科睿唯安同比增速更快（-1.4% vs -1.7%），过去两年Pediatrix Medical Group, Inc.的营收复合增速更高（-0.1% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
CLVT vs MD — 直观对比
营收规模更大
CLVT
是对方的1.2倍
$493.8M
营收增速更快
CLVT
高出0.3%
-1.7%
净利率更高
MD
高出13.7%
-6.9%
两年增速更快
MD
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $493.8M |
| 净利润 | $-40.2M | $33.7M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 5.2% | 9.9% |
| 净利率 | -6.9% | 6.8% |
| 营收同比 | -1.4% | -1.7% |
| 净利润同比 | 61.3% | 10.5% |
| 每股收益（稀释后） | $-0.06 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTMD
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $493.8M | ||
| Q3 25 | $623.1M | $492.9M | ||
| Q2 25 | $621.4M | $468.8M | ||
| Q1 25 | $593.7M | $458.4M | ||
| Q4 24 | $663.0M | $502.4M | ||
| Q3 24 | $622.2M | $511.2M | ||
| Q2 24 | $650.3M | $504.3M |
净利润CLVTMD
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $33.7M | ||
| Q3 25 | $-28.3M | $71.7M | ||
| Q2 25 | $-72.0M | $39.3M | ||
| Q1 25 | $-103.9M | $20.7M | ||
| Q4 24 | $-191.8M | $30.5M | ||
| Q3 24 | $-65.6M | $19.4M | ||
| Q2 24 | $-304.3M | $-153.0M |
毛利率CLVTMD
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — |
营业利润率CLVTMD
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 9.9% | ||
| Q3 25 | 7.1% | 13.8% | ||
| Q2 25 | 1.1% | 12.8% | ||
| Q1 25 | -3.5% | 7.0% | ||
| Q4 24 | -9.4% | 7.8% | ||
| Q3 24 | 3.5% | 6.6% | ||
| Q2 24 | -36.9% | -31.3% |
净利率CLVTMD
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 6.8% | ||
| Q3 25 | -4.5% | 14.5% | ||
| Q2 25 | -11.6% | 8.4% | ||
| Q1 25 | -17.5% | 4.5% | ||
| Q4 24 | -28.9% | 6.1% | ||
| Q3 24 | -10.5% | 3.8% | ||
| Q2 24 | -46.8% | -30.3% |
每股收益（稀释后）CLVTMD
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.40 | ||
| Q3 25 | $-0.04 | $0.84 | ||
| Q2 25 | $-0.11 | $0.46 | ||
| Q1 25 | $-0.15 | $0.24 | ||
| Q4 24 | $-0.27 | $0.37 | ||
| Q3 24 | $-0.09 | $0.23 | ||
| Q2 24 | $-0.46 | $-1.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $375.2M |
| 总债务越低越好 | $4.3B | $570.5M |
| 股东权益账面价值 | $4.8B | $865.9M |
| 总资产 | $10.9B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.89× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资CLVTMD
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $375.2M | ||
| Q3 25 | $318.7M | $340.1M | ||
| Q2 25 | $362.6M | $224.7M | ||
| Q1 25 | $354.0M | $99.0M | ||
| Q4 24 | $295.2M | $229.9M | ||
| Q3 24 | $388.5M | $103.8M | ||
| Q2 24 | $376.4M | $19.4M |
总债务CLVTMD
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $570.5M | ||
| Q3 25 | $4.4B | $577.2M | ||
| Q2 25 | $4.5B | $583.9M | ||
| Q1 25 | $4.5B | $590.5M | ||
| Q4 24 | $4.5B | $597.1M | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益CLVTMD
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $865.9M | ||
| Q3 25 | $4.9B | $890.7M | ||
| Q2 25 | $5.0B | $833.8M | ||
| Q1 25 | $5.0B | $789.2M | ||
| Q4 24 | $5.1B | $764.9M | ||
| Q3 24 | $5.5B | $732.5M | ||
| Q2 24 | $5.6B | $706.5M |
总资产CLVTMD
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $2.2B | ||
| Q3 25 | $11.2B | $2.2B | ||
| Q2 25 | $11.4B | $2.1B | ||
| Q1 25 | $11.5B | $2.0B | ||
| Q4 24 | $11.5B | $2.2B | ||
| Q3 24 | $12.0B | $2.1B | ||
| Q2 24 | $12.1B | $2.0B |
负债/权益比CLVTMD
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | 0.66× | ||
| Q3 25 | 0.90× | 0.65× | ||
| Q2 25 | 0.90× | 0.70× | ||
| Q1 25 | 0.90× | 0.75× | ||
| Q4 24 | 0.88× | 0.78× | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | — |
| 自由现金流率自由现金流/营收 | 13.5% | — |
| 资本支出强度资本支出/营收 | 9.5% | — |
| 现金转化率经营现金流/净利润 | — | 3.39× |
| 过去12个月自由现金流最近4个季度 | $333.9M | — |
8季度趋势，按日历期对齐
经营现金流CLVTMD
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $114.1M | ||
| Q3 25 | $181.1M | $137.3M | ||
| Q2 25 | $116.3M | $137.2M | ||
| Q1 25 | $171.2M | $-117.5M | ||
| Q4 24 | $141.3M | $133.0M | ||
| Q3 24 | $202.9M | $91.8M | ||
| Q2 24 | $126.2M | $107.0M |
自由现金流CLVTMD
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $50.3M | — | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $126.3M | — | ||
| Q2 24 | $60.3M | — |
自由现金流率CLVTMD
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 9.3% | — |
资本支出强度CLVTMD
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 12.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 10.1% | — |
现金转化率CLVTMD
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
